ArticleFrontiers in immunology2025
A case report of telitacicept in the treatment of immunocompromised and refractory lupus nephritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is a manifestation of kidney damage in systemic lupus erythematosus and is more common in Asian populations. The standard-of-care (SOC) for LN includes antimalarials, glucocorticoids, and immunosuppressants. The efficacy and safety of biologics have been validated, and they play an important role in the treatment of LN. This case report describes a patient with immunocompromised refractory LN who had repeated severe infections after SOC and visited the clinic for recurrence of LN combined with pneumonia. The patient was admitted to the hospital this time due to "recurrent rash for 15 years, edema for 2 years, and aggravation for 1 month". After anti-infective therapy, the treatment plan for glucocorticoids combined with telitacicept was individualized based on the patient's immune status, and the disease was quickly controlled. Simultaneously, it demonstrated efficacy and safety during follow-up, suggesting that telitacicept may be a new treatment option for refractory LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.